In Brief: Life Medical Sciences
This article was originally published in The Gray Sheet
Executive Summary
Life Medical Sciences: Company focusing development efforts on Repel bioresorable gel for adhesion prevention following early termination of its Piliel hair regrowth European clinical trial for the topical gel product. The company says it will submit an investigational device exemption to initiate U.S. trials of Repel-CV, a bioresorbable film designed to prevent post-operative adhesions following cardiovascular surgery. Data from a U.S. pilot study of the firm's Repel bioresorbable film for use in gynecological surgery show the product was "twice as effective in reducing adhesion formation compared to the control of standard surgical treatment." The device was particularly effective in treating adhesion formation on the posterior surface of the uterus. The company plans to seek FDA go-ahead for a pivotal trial in the U.S...